What is the 13F Pro Quality Score for IRWD?

13F Pro ranks IRONWOOD PHARMACEUTICALS INC (IRWD) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View IRWD's current score at https://13fpro.ai/research/IRWD (free sign-up required for the full ranking).

Which hedge funds own the most IRWD stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of IRWD include Context Capital Management,, ARMISTICE CAPITAL,, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/IRWD as soon as new 13F filings post.

Where does 13F Pro source IRWD data?

All IRONWOOD PHARMACEUTICALS INC fundamentals and ownership data come directly from SEC EDGAR. IRONWOOD PHARMACEUTICALS INC files with the SEC under CIK 1446847. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is IRWD in?

IRONWOOD PHARMACEUTICALS INC (IRWD) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is IRWD research updated on 13F Pro?

IRWD's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

IRONWOOD PHARMACEUTICALS INC(IRWD)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1446847 IRWD stock profile & AI dashboard →

13F Pro Quality Score

55.9/100

Rank #1,134 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

17.3/100

Profitability

86.7/100

Balance Sheet

94.8/100

Earnings Quality

30.0/100

Free Cash Flow

74.2/100

Institutional Flow

45.5/100

Revenue Scale

32.1/100

Dilution Risk

23.5/100

IRWD Stock Analysis & AI Quality Score

AI stock analysis and institutional research for IRONWOOD PHARMACEUTICALS INC (IRWD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IRWD at 55.9/100 on a 32-signal composite quality model, placing it at rank #1,134 of 2,879 stocks — the top half of the AI-ranked universe. IRWD scores in the top quartile across balance sheet strength (94.8), profitability (86.7). Areas of concern include revenue growth (17.3) and earnings quality (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 23.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), IRONWOOD PHARMACEUTICALS INC reports quarterly revenue of $106.5M, net income of $40.8M, free cash flow of $5.1M. Top institutional holders of IRWD by reported 13-F value include Context Capital Management,, ARMISTICE CAPITAL,, BlackRock,, based on the most recent SEC filings. IRWD trades on the Nasdaq exchange and files with the SEC under CIK 1446847. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IRWD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for IRONWOOD PHARMACEUTICALS INC directly from SEC EDGAR. IRONWOOD PHARMACEUTICALS INC's 13F Pro composite quality score has ranged between 8 and 71 since 2021, currently 55.9 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about IRONWOOD PHARMACEUTICALS INC

Quirks, history, and lore behind IRWD — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. specialty pharmaceutical company · listed on Nasdaq · focused on gastrointestinal and other disorders · headquartered in Massachusetts.
2
The Numbers
A small-cap biopharma with annual revenues in the low hundreds of millions — most of it riding on a single blockbuster GI drug.
3
The History
Founded around 1998, the company spent years in development before scoring a major FDA approval for a drug targeting irritable bowel syndrome with constipation and chronic idiopathic constipation.
4
The Secret
Its lead drug works by staying almost entirely in the gut — it's minimally absorbed into the bloodstream, which is a feature, not a bug, making it unusually well-tolerated.
5
The Lore
The company co-promoted its flagship product with AbbVie for years before eventually going solo — a divorce that tested whether it could stand on its own in a very unglamorous corner of medicine.
6
The Giveaway
Its drug Linzess (linaclotide) is one of the best-selling treatments for constipation-predominant IBS — and yes, the ticker rhymes with a certain dense, heavy metal.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$106.5M

Net Income

Q1 2026

$40.8M

Free Cash Flow

Q1 2026

$5.1M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-27.9% YoY

$296.2MFY 2025

FY19 $428.4MFY20 $389.5MFY22 $410.6MFY25 $296.2M

Net Income

-86.3% YoY

$24.0MFY 2025

FY19 $21.5MFY20 $106.2MFY22 $175.1MFY25 $24.0M

Operating Income

-60.7% YoY

$98.5MFY 2025

FY19 $120.1MFY20 $142.9MFY22 $250.3MFY25 $98.5M

EPS (Diluted)

-84.4% YoY

$0.15FY 2025

FY19 $0.14FY20 $0.66FY22 $0.96FY25 $0.15

Total Assets

-63.9% YoY

$396.9MFY 2025

FY19 $402.7MFY20 $559.2MFY22 $1.10BFY25 $396.9M

Total Debt

—FY 2025

FY19 —FY20 $430.3MFY22 $396.3MFY25 —

Op. Cash Flow

-53.6% YoY

$127.0MFY 2025

FY19 $10.7MFY20 $168.8MFY22 $273.8MFY25 $127.0M

Metric	FY 2025	FY 2022	FY 2020	FY 2019	FY 2017	FY 2016
Revenue	$296.2M -27.9%	$410.6M +5.4%	$389.5M -9.1%	$428.4M +43.6%	$298.3M +8.9%	$274.0M
Net Income	$24.0M -86.3%	$175.1M +64.9%	$106.2M +393.7%	$21.5M +118.4%	$-116.9M -43.1%	$-81.7M
Operating Income	$98.5M -60.7%	$250.3M +75.1%	$142.9M +19.0%	$120.1M +881.9%	$-15.4M +70.4%	$-51.9M
EPS (Diluted)	$0.15 -84.4%	$0.96 +45.5%	$0.66 +371.4%	$0.14	—	—
Total Assets	$396.9M -63.9%	$1.10B +96.8%	$559.2M +38.9%	$402.7M -33.5%	$605.7M -14.7%	$709.8M
Total Debt	—	$396.3M -7.9%	$430.3M	—	—	—
Operating Cash Flow	$127.0M -53.6%	$273.8M +62.1%	$168.8M +1474.2%	$10.7M +110.6%	$-100.8M -288.5%	$-25.9M

AI Insight: IRWD Financial Trends

Revenue volatility masks underlying profitability improvement, with operating income surging from $25M in Q2 2024 to $73M in Q1 2026.

• Operating income expanded from $25M in Q2 2024 to $73M in Q1 2026, despite revenue fluctuations.

• Equity deficit improved from -$322M in Q2 2024 to -$217M in Q1 2026.

• Revenue shows extreme quarter-to-quarter volatility, ranging from $41M to $122M across recent periods.

• Net income turned positive in recent quarters after losses, reaching $41M in Q1 2026.

⚠ Operating cash flow swung from $48M in Q3 2025 to just $5M in Q1 2026.

⚠ Revenue pattern remains highly unpredictable with no clear directional trend emerging over eight quarters.

AI Insight: IRWD Ratio Trends

Ironwood exhibits extreme quarterly volatility with operating margins swinging from -70.8% in Q1 2025 to 68.1% in Q1 2026.

• Operating margin surged from 14.3% in Q4 2025 to 68.1% in Q1 2026, marking highest level in dataset.

• Net profit margin jumped from -4.8% in Q4 2025 to 38.3% in Q1 2026, recovering from negative territory.

• Return on assets improved dramatically from -2.3% in Q4 2025 to 37.5% in Q1 2026.

⚠ Severe margin volatility continues with Q1 2025 showing -70.8% operating margin before recovery.

⚠ Q4 2025 marked sharp deterioration with operating margin falling from 61.8% to 14.3% quarter-over-quarter.

Get alerted when IRWD's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for IRONWOOD PHARMACEUTICALS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of IRWD

Context Capital Management, LLC
$58.1M59,619,000 sh
ARMISTICE CAPITAL, LLC
$52.7M15,028,000 sh
BlackRock, Inc.
$46.9M13,362,930 sh
JPMORGAN CHASE & CO
$46.1M46,942,000 sh
HIGHBRIDGE CAPITAL MANAGEMENT LLC
$46.1M46,942,000 sh
UBS Group AG
$39.3M11,200,320 sh
Sarissa Capital Management LP
$32.3M9,188,635 sh
BANK OF AMERICA CORP /DE/
$30.5M8,682,907 sh
D. E. Shaw & Co., Inc.
$28.7M29,150,000 sh
RENAISSANCE TECHNOLOGIES LLC
$28.3M8,061,073 sh

Fund	Value	Shares
Context Capital Management, LLC	$58.1M	59,619,000
ARMISTICE CAPITAL, LLC	$52.7M	15,028,000
BlackRock, Inc.	$46.9M	13,362,930
JPMORGAN CHASE & CO	$46.1M	46,942,000
HIGHBRIDGE CAPITAL MANAGEMENT LLC	$46.1M	46,942,000
UBS Group AG	$39.3M	11,200,320
Sarissa Capital Management LP	$32.3M	9,188,635
BANK OF AMERICA CORP /DE/	$30.5M	8,682,907
D. E. Shaw & Co., Inc.	$28.7M	29,150,000
RENAISSANCE TECHNOLOGIES LLC	$28.3M	8,061,073

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put IRWD on your watchlist

Track score changes the day IRONWOOD PHARMACEUTICALS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is IRWD a good stock to buy?

13F Pro's AI-powered analysis of IRONWOOD PHARMACEUTICALS INC (IRWD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IRWD are available on the IRWD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own IRWD?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IRWD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of IRONWOOD PHARMACEUTICALS INC's investment landscape.